AL
ALPRE.PA Predilife
- Market cap
- EUR 3.16M
- P/E
- -
- P/B
- 35.76x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 1.5/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ALPRE.PA undervalued?
Graham numberThe Graham number of Predilife cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Predilife fundamental analysis
3 of 11 checks passedROE 2/2
ROE surpassing expectations (104.8%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.
ROA 0/2
The stock's ROA (-74.9%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 2/2
With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.
DER 2/2
The stock has a low debt to equity ratio (-140%), which means it has a small amount of debt compared to the ownership it holds
Revenue Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Net Profit Growth 0/2
Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.
Assets Growth 0/2
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.
Graham Number 0/1
The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.
Dividend Growth 0/2
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.
Dividend 0/2
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.
Buffet Intrinsic Value 0/1
The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Predilife stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Predilife
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.
Full company profilePredilife financial statements
Predilife annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 8.00 | 42.0K | 72.3K | 22.9K | 51.6K | 142K | 289K | 318K | 618K | 1.12M |
| Gross Profit | -13.6K | 27.7K | 63.3K | -1.14M | -1.59M | -1.96M | 244K | 303K | 604K | 1.11M |
| Operating Income | -1.60M | -1.88M | -2.36M | -2.42M | -2.49M | -3.52M | -3.50M | -3.84M | -3.99M | -2.85M |
| EBITDA | -1.60M | -1.87M | -2.51M | -2.39M | -2.46M | -3.49M | -3.48M | -3.82M | -3.94M | -2.74M |
| Net Income | -1.49M | -1.65M | -2.37M | -2.10M | -2.25M | -3.41M | -3.65M | -4.22M | 199M | -3.52M |
| EPS | -0.51 | -0.60 | -0.86 | -0.71 | -0.66 | -0.94 | -1.00 | -1.14 | 54 | -0.94 |
| Balance Sheet | ||||||||||
| Total Assets | 2.48M | 1.01M | 2.31M | 1.35M | 4.10M | 3.97M | 4.75M | 8.82M | 2.44M | 1.83M |
| Total Liabilities | 2.11M | 2.30M | 2.32M | 2.11M | 3.37M | 5.53M | 9.97M | 8.30M | 6.71M | 8.75M |
| Shareholders' Equity | 363K | -1.29M | -12.1K | -764K | 722K | -1.57M | -5.22M | 514K | -4.27M | -6.91M |
| Cash & Short-term Investments | 2.01M | 623K | 1.53M | 390K | 3.24M | 2.92M | 3.82M | 3.43M | 1.06M | 557K |
| Total Debt | 2.12M | 2.07M | 1.55M | 1.49M | 2.74M | 5.13M | 7.34M | 7.18M | 4.95M | 5.52M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.36M | -1.53M | -1.81M | -2.39M | -2.11M | -3.83M | -3.07M | -4.23M | -3.72M | -2.56M |
| Capital Expenditure | 56.7K | 41.3K | 188K | 21.8K | 15.7K | 3.37K | 27.0K | 42.4K | 5.40K | 2.03K |
| Free Cash Flow | -1.41M | -1.57M | -2.00M | -2.42M | -2.12M | -3.83M | -3.09M | -4.27M | -3.73M | -2.57M |
| Ratios | ||||||||||
| ROE | -409.5% | - | - | - | -311.9% | - | - | -822.6% | - | - |
| ROA | -60.0% | -164.1% | -102.8% | -155.8% | -54.9% | -86.1% | -77.0% | -47.9% | 8,128.2% | -192.2% |
| Net Profit Margin | -18,563,437.5% | -3,940.1% | -3,281.3% | -9,191.2% | -4,364.1% | -2,402.7% | -1,266.3% | -1,329.2% | 32,137.4% | -315.3% |
| Debt to Equity | 5.85x | - | - | - | 3.79x | - | - | 13.99x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Predilife dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 1.55M | 0.42 | - |
| 2021 | EUR 2.55M | 0.70 | - |
| 2020 | - | - | - |
| 2019 | EUR 215K | 0.07 | - |
| 2018 | EUR 91.0K | 0.03 | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:1 on Dec 24, 2020.
Who owns Predilife
- Insiders 50.95%
- Institutions 0.00%
- Public & others 49.05%
- Shares outstanding 3.94M
- Free float 997K
Predilife company profile
- Company name
- Predilife
- Ticker
- ALPRE.PA
- ISIN
- FR0010169920
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- 39 Rue Camille Desmoulins, Villejuif, France, 94805
- Phone
- 33 9 72 22 67 08
- Website
- predilife.com
About Predilife
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.
Predilife management
4- Mr. Stephane RagusaFounder, President, CEO & Chairman · born 1970
- Mr. Émilien GauthierChief Technical Officer
- Marion RenelierLegal Director & Data Protection Officer
- Anne KerzanChief Marketing Officer